Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
REGENXBIO INC (RGNX) Stock Price & Overview
NASDAQ:RGNX • US75901B1070
Current stock price
8.97 USD
+0.57 (+6.79%)
At close:
8.97 USD
0 (0%)
After Hours:
The current stock price of RGNX is 8.97 USD. Today RGNX is up by 6.79%. In the past month the price increased by 3.94%. In the past year, price decreased by -13.75%.
RGNX Key Statistics
52-Week Range6.89 - 16.19
Current RGNX stock price positioned within its 52-week range.
1-Month Range8.1 - 9.67
Current RGNX stock price positioned within its 1-month range.
- Market Cap
- 462.942M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.76
- Dividend Yield
- N/A
RGNX Stock Performance
Today
+6.79%
1 Week
-0.22%
1 Month
+3.94%
3 Months
-19.62%
Longer-term
6 Months -29.76%
1 Year -13.75%
2 Years -41.56%
3 Years -53.67%
5 Years -74.14%
10 Years -13.92%
RGNX Stock Chart
RGNX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to RGNX. When comparing the yearly performance of all stocks, RGNX is a bad performer in the overall market: 84.29% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
RGNX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to RGNX. RGNX may be in some trouble as it scores bad on both profitability and health.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
RGNX Earnings
On March 5, 2026 RGNX reported an EPS of -1.3 and a revenue of 30.34M. The company missed EPS expectations (-33.31% surprise) and missed revenue expectations (-18.65% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported-$1.30
Revenue Reported30.337M
EPS Surprise -33.31%
Revenue Surprise -18.65%
RGNX Forecast & Estimates
19 analysts have analysed RGNX and the average price target is 30.26 USD. This implies a price increase of 237.35% is expected in the next year compared to the current price of 8.97.
For the next year, analysts expect an EPS growth of 32.92% and a revenue growth 42.69% for RGNX
Analysts
Analysts84.21
Price Target30.26 (237.35%)
EPS Next Y32.92%
Revenue Next Year42.69%
RGNX Index Membership
RGNX is currently included in the following stock indexes tracked on ChartMill.
RGNX Financial Highlights
Over the last trailing twelve months RGNX reported a non-GAAP Earnings per Share(EPS) of -3.76. The EPS increased by 17.54% compared to the year before.
Income Statements
Revenue(TTM)170.44M
Net Income(TTM)-193.88M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.8% | ||
| ROE | -188.72% | ||
| Debt/Equity | 1.43 |
Chartmill High Growth Momentum
EPS Q2Q%-28.71%
Sales Q2Q%43%
EPS 1Y (TTM)17.54%
Revenue 1Y (TTM)104.54%
RGNX Ownership
Ownership
Inst Owners79.95%
Shares51.61M
Float46.65M
Ins Owners7.55%
Short Float %14.89%
Short Ratio8.79
RGNX Industry Overview
RGNX operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
13/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
27%
Outperformed 27% of sub-industries
3 Month Rank
47%
Outperformed 47% of sub-industries
6 Month Rank
30%
Outperformed 30% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 4.1%
- New Lows
- 4.6%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.7%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.4
- Average Fwd P/E
- 22.3
- Average Debt/Equity
- 2.2
RGNX Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 12.88 | 360.632B | ||
| AMGN | AMGEN INC | 15.16 | 182.426B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 159.919B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.94 | 107.655B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.82 | 72.562B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.34 | 40.188B | ||
| INSM | INSMED INC | N/A | 29.146B | ||
| BIIB | BIOGEN INC | 11.58 | 28.527B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.853B | ||
| NTRA | NATERA INC | N/A | 27.602B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.55 | 25.03B | ||
| INCY | INCYTE CORP | 10.43 | 19.722B | ||
| MRNA | MODERNA INC | N/A | 18.132B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About RGNX
Company Profile
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 371 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The firm is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Company Info
IPO: 2015-09-17
REGENXBIO INC
9804 Medical Center Drive
Rockville MARYLAND 20850 US
CEO: Kenneth T. Mills
Employees: 371
Phone: 12405528181
REGENXBIO INC / RGNX FAQ
What does REGENXBIO INC do?
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 371 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The firm is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
What is the current price of RGNX stock?
The current stock price of RGNX is 8.97 USD. The price increased by 6.79% in the last trading session.
Does REGENXBIO INC pay dividends?
RGNX does not pay a dividend.
How is the ChartMill rating for REGENXBIO INC?
RGNX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the market capitalization of RGNX stock?
REGENXBIO INC (RGNX) has a market capitalization of 462.94M USD. This makes RGNX a Small Cap stock.
Can you provide the ownership details for RGNX stock?
You can find the ownership structure of REGENXBIO INC (RGNX) on the Ownership tab.
What is the Short Interest ratio of REGENXBIO INC (RGNX) stock?
The outstanding short interest for REGENXBIO INC (RGNX) is 14.89% of its float.